Abstract
Cancer immunotherapy attempts to harness the immune system by breaking tolerance and generating a robust anticancer response. we have recently demonstrated a synergistic enhancement in tumor clearance following therapeutic, dual PD-1 and LAG-3 blockade. here, we discuss the implications of these fndings in the context of future combinatorial immunotherapeutic approaches.
Original language | English (US) |
---|---|
Pages (from-to) | 1172-1174 |
Number of pages | 3 |
Journal | OncoImmunology |
Volume | 1 |
Issue number | 7 |
DOIs | |
State | Published - 2012 |
Keywords
- Cancer
- CD152
- CD223
- CD279
- CTLA-4
- Immunotherapy
- Ipilimumab
- LAG-3
- Lymphocyte
- MDX-1106
- PD-1
- Synergy
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology